Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

Infection and Immunity

Volumn 69, Issue 8, 2001, Pages 4719-4725

  Melby, P C ^a   Yang, J ^a   Zhao, W ^a   Perez, L E ^a   Cheng, J ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; LACK ANTIGEN; LEISHMANIA VACCINE; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; IMMUNOGENICITY; INFECTION PREVENTION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; SKIN LEISHMANIASIS; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; BASE SEQUENCE; CONSERVED SEQUENCE; DISEASE MODELS, ANIMAL; DNA, PROTOZOAN; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; VACCINATION; VACCINES, DNA;

EID: 0034911854     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.8.4719-4725.2001     Document Type: Article

References (47)

1. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
2. Basic local alignment search tool
3. New perspectives on a subclinical form of visceral leishmaniasis
4. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated
5. Cell-mediated immunity in American visceral leishmaniasis: Reversible immunosuppression during acute infection
6. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
7. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63
8. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites
9. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis
10. Superiority of the ear pinna over muscle tissue as site for DNA vaccination
11. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection
12. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
13. Vaccination with DNA encoding the immunodominant. LACK parasite antigen confers protective immunity to mice infected with Leishmania major
14. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response
15. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis
16. Immunoprotective Leishmania major synthetic T cell epitopes
17. CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice
18. Resistance to Leishmania major induced by tolerance to a single antigen
19. Differential production of Th1-h7 and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
20. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice
21. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness
22. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice
23. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo
24. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library
25. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani
26. Expression cloning of a protective Leishmania antigen
27. Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity
28. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major
29. Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope
30. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages
31. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis
32. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase
33. Control of Leishmania major by a monoclonal alpha beta T cell repertoire
34. Animal models for the analysis of immune responses to leishmaniasis
35. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani
36. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection
37. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes
38. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge
39. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection
40. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis
41. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis
42. Studies in the epidemiology of East African leishmaniasis. 5. Leishmania adleri and natural immunity
43. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
44. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis
45. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
46. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice
47. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major